Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice

Clinical Immunology

Volumn 162, Issue , 2016, Pages 58-73

  Regna, Nicole L ^a   Vieson, Miranda D ^a   Luo, Xin M ^a   Chafin, Cristen B ^a   Puthiyaveetil, Abdul Gafoor ^b   Hammond, Sarah E ^a   Caudell, David L ^c   Jarpe, Matthew B ^d   Reilly, Christopher M ^a,e  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b AMERICAN UNIVERSITY OF RAS AL KHAIMAH   (United Arab Emirates)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d Acetylon Pharmaceuticals   (United States)

^e EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

B cells; HDAC; Systemic lupus erythematosus; T cells

Indexed keywords

ACY 738; DOUBLE STRANDED DNA ANTIBODY; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ENZYME INHIBITOR; HDAC6 PROTEIN, MOUSE; HISTONE DEACETYLASE; HYDROXAMIC ACID; N-HYDROXY-2-(1-PHENYLCYCLOPROYLAMINO)PYRIMIDINE-5-CARBOXAMIDE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BODY WEIGHT; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEVELOPMENTAL STAGE; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GLOMERULONEPHRITIS; IMMUNE COMPLEX DEPOSITION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEINURIA; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SPLENOMEGALY; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ANIMAL; CYTOLOGY; DRUG EFFECTS; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEW ZEALAND BLACK MOUSE; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN;

ANIMALS; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED NZB; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; SPLEEN;

EID: 84947815530     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.11.007     Document Type: Article

References (88)

1. Crispin J.C., et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol. Med. 2010, 16:47-57.
2. Grammer A.C., Lipsky P.E. B cell abnormalities in systemic lupus erythematosus. Arthritis Res. Ther. 2003, 5(Suppl 4):S22-S27.
3. Mok C.C., Lau C.S. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 2003, 56:481-490.
4. Alvarado-Sanchez B., et al. Regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 2006, 27:110-118.
5. Regna N.L., et al. Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo. Clin. Immunol. 2014, 151:29-42.
6. Xing Q., Wang B., Su H., Cui J., Li J. Elevated Th17 cells are accompanied by FoxP3+ treg cells decrease in patients with lupus nephritis. Rheumatol. Int. 2011.
7. Crispin J.C., et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J. Immunol. 2008, 181:8761-8766.
8. Burnett R., Ravel G., Descotes J. Clinical and histopathological progression of lesions in lupus-prone (NZB x NZW) F1 mice. Exp. Toxicol. Pathol. 2004, 56:37-44.
9. Theofilopoulos A.N., Dixon F.J. Murine models of systemic lupus erythematosus. Adv. Immunol. 1985, 37:269-390.
10. Hardy R.R., Hayakawa K. B cell development pathways. Annu. Rev. Immunol. 2001, 19:595-621.
11. Hardy R.R., Carmack C.E., Shinton S.A., Kemp J.D., Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 1991, 173:1213-1225.
12. Alt F.W., et al. Ordered rearrangement of immunoglobulin heavy chain variable region segments. EMBO J 1984, 3:1209-1219.
13. Ehlich A., et al. Immunoglobulin heavy and light chain genes rearrange independently at early stages of B cell development. Cell 1993, 72:695-704.
14. Kyttaris V.C., Juang Y.T., Tsokos G.C. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr. Opin. Rheumatol. 2005, 17:518-522.
15. Apostolidis S.A., Lieberman L.A., Kis-Toth K., Crispin J.C., Tsokos G.C. The dysregulation of cytokine networks in systemic lupus erythematosus. J. Interf. Cytokine Res. 2011, 31:769-779.
16. Sfikakis P.P., Karali V., Lilakos K., Georgiou G., Panayiotidis P. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after therapeutic B-cell depletion. Clin. Immunol. 2009, 132:19-31.
17. Dorner T., Giesecke C., Lipsky P.E. Mechanisms of B cell autoimmunity in SLE. Arthritis Res. Ther. 2011, 13:243.
18. Anolik J., Sanz I. B cells in human and murine systemic lupus erythematosus. Curr. Opin. Rheumatol. 2004, 16:505-512.
19. Korganow A.S., et al. Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression. J. Autoimmun. 2010, 34:426-434.
20. Jacob N., Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity 2010, 43:84-97.
21. Stohl W., Looney R.J. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?. Clin. Immunol. 2006, 121:1-12.
22. Cambridge G., et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 2008, 67:1011-1016.
23. Furtado J., Isenberg D.A. B cell elimination in systemic lupus erythematosus. Clin. Immunol. 2013, 146:90-103.
24. Liossis S.N., Sfikakis P.P. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin. Immunol. 2008, 127:280-285.
25. Chen C., Rowell E.A., Thomas R.M., Hancock W.W., Wells A.D. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem 2006, 281:36828-36834.
26. Geiman T.M., Robertson K.D. Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together?. J. Cell. Biochem. 2002, 87:117-125.
27. Hu N., et al. Abnormal histone modification patterns in lupus CD4+ T cells. J. Rheumatol. 2008, 35:804-810.
28. Picascia A., et al. Epigenetic control of autoimmune diseases: from bench to bedside. Clin. Immunol. 2015, 157:1-15.
29. Hedrich C.M., Tsokos G.C. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol. Med. 2011, 17:714-724.
30. Wu H., Zhao M., Chang C., Lu Q. The real culprit in systemic lupus erythematosus: abnormal epigenetic regulation. Int. J. Mol. Sci. 2015, 16:11013-11033.
31. Wallace J.L., Braquet P., Ibbotson G.C., MacNaughton W.K., Cirino G. Assessment of the role of platelet-activating factor in an animal model of inflammatory bowel disease. Journal of Lipid Mediators 1989, 1:13-23.
32. Reilly C.M., Regna N., Mishra N. HDAC inhibition in lupus models. Mol. Med. 2011, 17:417-425.
33. Dinarello C.A., Fossati G., Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol. Med. 2011, 17:333-352.
34. Zhao S., Long H., Lu Q. Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers, and therapeutic potentials. Clin. Rev. Allergy Immunol. 2010, 39:3-9.
35. Guo Y., Sawalha A.H., Lu Q. Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application. Clin. Immunol. 2014, 155:79-90.
36. Kim H.J., Bae S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 2011, 3:166-179.
37. Glozak M.A., Sengupta N., Zhang X., Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
38. Kelly W.K., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 2003, 9:3578-3588.
39. de Zoeten E.F., et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol. Cell. Biol. 2011, 31:2066-2078.
40. Lal G., Bromberg J.S. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009, 114:3727-3735.
41. van Loosdregt J., et al. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 2010, 115:965-974.
42. Beier U.H., et al. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms. Sci. Signal. 2012, 5:ra45.
43. Hancock W.W. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation. Handb. Exp. Pharmacol. 2011, 206:103-123.
44. Zhang Y., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol. Cell. Biol. 2008, 28:1688-1701.
45. Reilly C.M., et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun. 2008, 31:123-130.
46. Koenen H.J., et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112:2340-2352.
47. Akimova, T. et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin. Immunol. 136, 348-363.
48. Wang L., et al. Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One 2012, 7.
49. Jochems J., et al. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Neuropsychopharmacology 2014, 39:389-400.
50. Jochems J., et al. Enhancement of stress resilience through histone deacetylase 6-mediated regulation of glucocorticoid receptor chaperone dynamics. Biol. Psychiatry 2015, 77:345-355.
51. Grimaldi C.M., Michael D.J., Diamond B. Cutting edge: expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. J. Immunol. 2001, 167:1886-1890.
52. Odendahl M., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 2000, 165:5970-5979.
53. Tsokos G.C., Balow J.E. Phenotypes of T lymphocytes in systemic lupus erythematosus: decreased cytotoxic/suppressor subpopulation is associated with deficient allogeneic cytotoxic responses rather than with concanavalin a-induced suppressor cells. Clin. Immunol. Immunopathol. 1983, 26:267-276.
54. Hammond D.M., et al. Double-negative T cells from MRL-lpr/lpr mice mediate cytolytic activity when triggered through adhesion molecules and constitutively express perforin gene. The Journal of Experimental Medicine 1993, 178:2225-2230.
55. Sakaguchi S., et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 2006, 212:8-27.
56. Horwitz D.A. Regulatory T cells in systemic lupus erythematosus: past, present and future. Arthritis Res. Ther. 2008, 10:227.
57. Vyse T.J., et al. Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice. J. Clin. Invest. 1996, 98:1762-1772.
58. Ehlers M., Fukuyama H., McGaha T.L., Aderem A., Ravetch J.V. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med 2006, 203:553-561.
59. Handwerger B.S., Rus V., da Silva L., Via C.S. The role of cytokines in the immunopathogenesis of lupus. Springer Semin. Immunopathol. 1994, 16:153-180.
60. Dean G.S., Tyrrell-Price J., Crawley E., Isenberg D.A. Cytokines and systemic lupus erythematosus. Ann. Rheum. Dis. 2000, 59:243-251.
61. Ohtsuka K., Gray J.D., Stimmler M.M., Toro B., Horwitz D.A. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J. Immunol. 1998, 160:2539-2545.
62. Dixon F.J. Murine SLE models and autoimmune disease. Hospital Practice 1982, 17:63-73.
63. McMurray R.W., Hoffman R.W., Nelson W., Walker S.E. Cytokine mRNA expression in the B/W mouse model of systemic lupus erythematosus-analyses of strain, gender, and age effects. Clin. Immunol. Immunopathol. 1997, 84:260-268.
64. Ishida H., et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994, 179:305-310.
65. Saxena V., et al. Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage. J. Immunol. 2008, 180:1903-1912.
66. Aringer M., Smolen J.S. Cytokine expression in lupus kidneys. Lupus 2005, 14:13-18.
67. Lo M.S., Tsokos G.C. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann. N. Y. Acad. Sci. 2012, 1247:138-152.
68. Paz Z., Tsokos G.C. New therapeutics in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2013, 25:297-303.
69. Yurasov S., et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005, 201:703-711.
70. Lu L., Chaudhury P., Osmond D.G. Regulation of cell survival during B lymphopoiesis: apoptosis and Bcl-2/Bax content of precursor B cells in bone marrow of mice with altered expression of IL-7 and recombinase-activating gene-2. J. Immunol. 1999, 162:1931-1940.
71. Mizuta R., Mizuta M., Araki S., Kitamura D. RAG2 is down-regulated by cytoplasmic sequestration and ubiquitin-dependent degradation. J Biol Chem 2002, 277:41423-41427.
72. Lu L., Osmond D.G. Apoptosis and its modulation during B lymphopoiesis in mouse bone marrow. Immunol. Rev. 2000, 175:158-174.
73. Lian Z.X., et al. Increased frequency of pre-pro B cells in the bone marrow of New Zealand Black (NZB) mice: implications for a developmental block in B cell differentiation. Dev. Immunol. 2002, 9:35-45.
74. Hanrotel-Saliou C., Segalen I., Le Meur Y., Youinou P., Renaudineau Y. Glomerular antibodies in lupus nephritis. Clin. Rev. Allergy Immunol. 2011, 40:151-158.
75. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
76. Hayashi T., Hasegawa K., Adachi C. Elimination of CD4(+)CD25(+) T cell accelerates the development of glomerulonephritis during the preactive phase in autoimmune-prone female NZB x NZW F mice. Int. J. Exp. Pathol. 2005, 86:289-296.
77. + T cells selectively kill B lymphocytes. Blood 2006, 107:3925-3932.
78. Cao T., Wenzel S.E., Faubion W.A., Harriman G., Li L. Enhanced suppressive function of regulatory T cells from patients with immune-mediated diseases following successful ex vivo expansion. Clin. Immunol. 2010, 136:329-337.
79. Zhou L., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.
80. Grande J.P. Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring. Lupus 1998, 7:604-610.
81. Strutz F., Neilson E.G. New insights into mechanisms of fibrosis in immune renal injury. Springer Semin. Immunopathol. 2003, 24:459-476.
82. DolffS., et al. Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin. Immunol. 2011, 141:197-204.
83. Arora V., et al. Cytokine imbalance in systemic lupus erythematosus: a study on northern Indian subjects. Lupus 2012, 21:596-603.
84. Luan H.Y., et al. Monoclonal anti-double-stranded DNA antibodies cross-react with phosphoglycerate kinase 1 and inhibit the expression and production of IL-2 in activated Jurkat T cell line. Clin. Immunol. 2006, 120:326-334.
85. Maeda K., Mehta H., Drevets D.A., Coggeshall K.M. IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood 2010, 115:4699-4706.
86. Maczynska I., et al. Proinflammatory cytokine (IL-1beta, IL-6, IL-12, IL-18 and TNF-alpha) levels in sera of patients with subacute cutaneous lupus erythematosus (SCLE). Immunol. Lett. 2006, 102:79-82.
87. Shaw P.J., McDermott M.F., Kanneganti T.D. Inflammasomes and autoimmunity. Trends Mol. Med. 2011, 17:57-64.
88. Voronov E., et al. IL-1 beta-deficient mice are resistant to induction of experimental SLE. Eur. Cytokine Netw. 2006, 17:109-116.